Accumulating evidence has demonstrated that when BRD7 is downregulated it becomes associated with negative clinical outcomes in multiple types of malignant tumors, including breast cancer, colorectal cancer, and non-small cell lung cancer, suggesting that BRD7 may serve as a tumor suppressor gene, thereby interfering with efficient cancer development and progression 10,11. This evidence concerns the gene BRD7 and breast cancer.